Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday. In February 2013, U.S. regulators unexpectedly refused to approve Tresiba until the group conducted extra tests over potential heart risks, dealing a major blow to one of Novo Nordisk’s key products as well as to its share price. “We judge that we still have an opportunity to launch Tresiba in the United States, if we are successful in the trials, before any significant competitive products are being entered into the market,” Lars Rebien Sorensen told the company’s annual general meeting.
Help employers find you! Check out all the jobs and post your resume.
